Upload Image (Max 20MB per Image)
Albany Molecular Research (AMRI) and Chai Therapeutics, an affiliate of Bessor Pharma, have signed a licensing deal to develop tubulin inhibitor compound, ALB 109564(a), for cancer treatment. AMRI's ALB 109564(a) is a novel analog ...
Tags: AMRI, Chai Therapeutics, tubulin inhibitor compound